AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 2.68 USD
Market Cap: 265.2m USD
Have any thoughts about
AC Immune SA?
Write Note

AC Immune SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AC Immune SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
AC Immune SA
NASDAQ:ACIU
Income from Continuing Operations
-CHf39.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Income from Continuing Operations
-$234.5m
CAGR 3-Years
2%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Income from Continuing Operations
-$239.6m
CAGR 3-Years
N/A
CAGR 5-Years
-84%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Income from Continuing Operations
-CHf69.1m
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Income from Continuing Operations
-CHf652k
CAGR 3-Years
76%
CAGR 5-Years
51%
CAGR 10-Years
33%
Kuros Biosciences AG
SIX:KURN
Income from Continuing Operations
-CHf8.9m
CAGR 3-Years
-15%
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

AC Immune SA
Glance View

Market Cap
265.9m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
12.88 USD
Undervaluation 79%
Intrinsic Value
Price

See Also

What is AC Immune SA's Income from Continuing Operations?
Income from Continuing Operations
-39.9m CHF

Based on the financial report for Sep 30, 2024, AC Immune SA's Income from Continuing Operations amounts to -39.9m CHF.

What is AC Immune SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
18%

Over the last year, the Income from Continuing Operations growth was 42%. The average annual Income from Continuing Operations growth rates for AC Immune SA have been 18% over the past three years .

Back to Top